Navigation Links
BiologicsMD, Inc. Announces The Appointment of J. David Owens as Chief Executive Officer
Date:7/16/2013

Fayetteville, Arkansas (PRWEB) July 16, 2013

BiologicsMD, Inc., a privately held drug discovery company developing innovative biologic therapeutics for improving bone health, announced that it has appointed J. David Owens to the company’s newly created CEO position. Mr. Owens brings a long and successful track record within both the pharmaceutical and biotechnology industries, having managed billion dollar business units within multi-national pharmaceutical companies and also built early stage businesses that successfully attracted capital and strategic partners.

Most recently, Mr. Owens was the Chief Business Officer for Novira Therapeutics, Inc., a privately held antiviral drug discovery company developing innovative, first-in-class therapeutics for the treatment of viral diseases. While there, he co-led a syndicated angel investment in 2011 and then a Series A financing in 2012. Prior to Novira, Mr. Owens held executive positions as Senior Vice President, and Business Unit Head of the Surgical Products Division at King Pharmaceuticals (now part of Pfizer) and prior to that as Vice President of Global Marketing & Medical Affairs at Aventis Pharma (now part of Sanofi). Earlier in his career, Mr. Owens held commercial operations roles at Genentech, Merck and Abbott Labs. He is also a member of the Selection Team and a Business Advisor to the University City Science Center (QED Program), one of the United State’s oldest urban incubators located in Philadelphia, PA. Mr. Owens is a graduate of the University of Wisconsin, School of Pharmacy and a Registered Pharmacist.

“I’m very excited to join the BiologicsMD team at this very important stage in advancing the company’s lead development drug, PTH-CBD™, towards the clinic,” said Mr. Owens. “The team and the Board have done an excellent job of getting the technology to the preclinical stage. Now we will prove that PTH-CBD™ is a novel and important new tool in treating human disease.”

“We are very pleased that David has joined the BiologicsMD team and will guide the company into its next stage of development. David brings an outstanding set of skills and experiences and also has the industry contacts needed to help BiologicsMD obtain strategic partnerships as the company approaches the clinic,” stated Dr. Calvin Goforth, Chairman of the BiologicsMD, Inc. Board of Directors.

BiologicsMD, Inc. is an early stage therapeutics company that focuses on novel technologies to actively improve bone health. The company has an exclusive license to develop a new biologic therapeutic, PTH-CBD™, that selectively binds to bone and stimulates new bone growth. PTH-CBD is a molecular fusion of PTH (1-33) with the Collagen Binding Domain (CBD) of ColH collagenase. The CBD binds to type 1 collagen, thus delivering PTH directly to the bone, where it can be most effective in building new bone. The company was founded in 2010 and to date, the company has both raised private equity and has been awarded a $2.3 million research contract from the Department of Defense. BiologicsMD™ is a VIC Technology Venture Development™ portfolio company.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10928698.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. AFAR announces the 2012 Hartford Centers of Excellence in Geriatric Medicine awards
2. Bascom Palmer Eye Institute announces breakthrough for degenerative vision disorder
3. University of Houston Graduate College of Social Work announces partnership with MD Anderson
4. The Ludwig Institute for Cancer Research announces launch of iTeos Therapeutics SA
5. AGA announces prestigious awards recognition recipients
6. TheBestHeartRateMonitorReviews.com Announces The Top 3 Heart Rate Monitors
7. Article Marketing Company Content Writing King Announces Training Of New Graphic Design Artist
8. Zane Benefits Announces Wellness HRAs: A New Way to Reward Healthy Employees
9. San Francisco’s Advanced Male Medical Center Announces Discount, Discusses Erectile Dysfunction
10. Insulite Labs announces the launch of the PCOS Inspiration Hour, a one hour virtual gathering place for women with PCOS and other women’s health issues to come together.
11. NYC Doc Announces 3 Surprising Ways to Beat Seasonal Allergies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... ... ... Comfort Keepers® of San Diego, CA is excited to announce they are ... drive cancer patients to and from their cancer treatments. Comfort Keepers provides quality ... and ongoing independence. Getting to and from medical treatments is one of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... pluripotent stem (iPS) cells and other difficult to transfect cells, announces its launch ... PluriQ™ G9™ Gene Editing System is a complete system for culturing ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American Respiratory ... testing company, is now able to perform sophisticated lung assessments in ... Medical Technologies , Inc. Patients are no longer ... to ndd,s EasyOne PRO ® , ARL patients like Jeanne R. ... testing done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
Breaking Medicine Technology: